In our patients who were assessed yearly for the recurrence of MEN1 features, recurrences were rapidly detected and corrected, with the result being that we saw no effect of the presence of MEN1 (i.e., hyperparathyroidism) on drug maintenance doses. The gene discussed is MEN1; the disease is hyperparathyroidism.